

# Hemophilia Treatment Market Forecasts to 2030 – Global Analysis By Hemophilia Type (Hemophilia A, Hemophilia B, Hemophilia C, Acquired Hemophilia and Other Hemophilia Types), Treatment Type, Route of Administration, End User and By Geography

<https://marketpublishers.com/r/HCCFD28ECCE2EN.html>

Date: April 2025

Pages: 150

Price: US\$ 4,150.00 (Single User License)

ID: HCCFD28ECCE2EN

## Abstracts

According to Statistics MRC, the Global Hemophilia Treatment Market is accounted for \$13.7 billion in 2024 and is expected to reach \$20.6 billion by 2030 growing at a CAGR of 7.0% during the forecast period. Hemophilia treatment entails treating and preventing excessive bleeding in people who have hemophilia, a genetic illness that affects blood clotting. In order to restore normal clotting, the main strategy is replacement therapy, which involves injecting clotting factors VIII (for hemophilia A) or IX (for hemophilia B). Additional therapies include gene therapy for long-term correction, antifibrinolytic medications to stop clot breakdown, and desmopressin (DDAVP) for mild cases. Prophylactic (preventive) measures aid in lowering the frequency of unplanned bleeding episodes.

Market Dynamics:

Driver:

Increasing Prevalence of Hemophilia

The rising prevalence of hemophilia is fueling significant growth in the market. The need for advanced therapeutics, including as gene therapy, recombinant clotting factors, and longer half-life treatments, is being driven by an increase in the number of patients. Prophylactic treatment adoption is increasing as a result of increased patient knowledge and better diagnosis. Market expansion is also being aided by government programs

and healthcare subsidies. Pharmaceutical firms are making investments in cutting-edge solutions to satisfy rising demand, which is speeding up market expansion and accessibility.

Restraint:

#### High Treatment Costs

The high cost of hemophilia treatment significantly hinders market growth by limiting patient access to essential therapies. Expensive clotting factor replacement therapies, gene therapies, and prolonged treatment regimens impose a financial burden on healthcare systems and patients, particularly in low- and middle-income countries. This leads to reduced diagnosis rates, treatment discontinuation, and reliance on inadequate alternatives, ultimately restraining market expansion and innovation in hemophilia care.

Opportunity:

#### Expanding Healthcare Infrastructure

Expanding healthcare infrastructure boosts the industry by increasing access to sophisticated medicines, diagnostic facilities, and specialist care. Investing more in clinics, hospitals, and research facilities improves early diagnosis and prompt treatment, which lowers problems. Public-private partnerships, insurance coverage, and government initiatives all contribute to market expansion. Better cold chain logistics and distribution networks also make clotting factor medicines and new gene therapies more widely available, especially in developing nations, which eventually improves patient outcomes and propels market expansion.

Threat:

#### Risk of Inhibitor Development

The risk of inhibitor development negatively impacts the hemophilia treatment market by reducing the effectiveness of standard clotting factor therapies, leading to increased treatment complexity and costs. Patients with inhibitors require alternative, expensive therapies like bypassing agents or gene therapy, limiting market growth. Additionally, managing inhibitors demands frequent monitoring and specialized care, straining healthcare resources. This challenge hinders patient outcomes, discourages treatment

adoption, and slows overall market expansion.

### Covid-19 Impact

The COVID-19 pandemic disrupted the hemophilia treatment market by delaying diagnoses, reducing hospital visits, and affecting supply chains. Many patients faced difficulties accessing essential therapies due to lockdowns and healthcare system strain. However, the market saw increased adoption of home-based treatments and digital health solutions. As healthcare systems recovered, demand rebounded, driving innovation in gene therapy and extended half-life treatments for improved patient outcomes.

The gene therapy segment is expected to be the largest market share during the forecast period

The gene therapy segment is expected to account for the largest market share during the forecast period because long-term factor production is made possible by advanced therapies such as adeno-associated virus (AAV)-based gene transfer, which enhances patient outcomes and quality of life. The market is expanding more quickly because of more approvals, higher R&D expenditures, and growing demand for curative treatments. Furthermore, gene therapy is becoming more and more popular in the treatment of hemophilia due to its lifetime cost-effectiveness when compared to traditional medicines.

The desmopressin segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the desmopressin segment is predicted to witness the highest growth rate, because desmopressin promotes the release of von Willebrand factor and stored factor VIII; it lowers the risk of bleeding and the frequency of clotting factor infusions. Patient compliance is improved by its simplicity of administration and availability in injectable and intranasal forms. Its demand is further fueled by growing awareness, growing use in emergency situations, and formulation developments, all of which have a favorable impact on the growth of the hemophilia treatment market as a whole.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest

market share due to growing prevalence of hemophilia, along with favorable reimbursement policies, boosts market growth. Key pharmaceutical advancements, such as extended half-life therapies and recombinant factor products, enhance treatment efficacy. Additionally, government initiatives and research funding support innovation. The presence of major industry players, coupled with patient advocacy groups, further accelerates market expansion. Technological advancements in personalized medicine also contribute to improved treatment outcomes.

#### Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, because of easier access to care, especially in developing nations like China and India. Prophylactic treatments are increasingly being used instead of on-demand ones, which is decreasing problems and increasing demand for gene therapy and factor replacement treatments. The availability of treatments is also being improved by partnerships between pharmaceutical companies and healthcare providers, and the market is expanding due to an older population with inherited bleeding problems.

#### Key players in the market

Some of the key players profiled in the Hemophilia Treatment Market include Takeda Pharmaceutical Company Limited, Octapharma AG., CSL Behring, Medtronic, Pfizer, Inc., Novo Nordisk A/S., Bayer AG, Allergan, BioMarin, Aptevo Therapeutics, Spark Therapeutics, Inc., AscellaHealth, Sanofi, Baxter International and F. Hoffmann La-Roche Ltd.

#### Key Developments:

In September 2024, Medtronic expanded aible spine surgery ecosystem with new technologies and Siemens Healthineers partnership, These enhancements are designed to advance AiBLE™, the Medtronic smart ecosystem of innovative navigation, robotics, data and AI, imaging, software and implants that enable more predictable outcomes in spine and cranial procedures.

In August 2024, Pfizer Inc. introduced PfizerForAll, a user-friendly digital platform designed to make access to healthcare and managing health and wellness more seamless for people across the U.S.

#### Hemophilia Types Covered:

Hemophilia A

Hemophilia B

Hemophilia C

Acquired Hemophilia

Other Hemophilia Types

#### Treatment Types Covered:

Factor Replacement Therapies

Desmopressin

Gene Therapy

Antifibrinolytics

Other Treatment Types

#### Administrations Covered:

Intravenous (IV) Administration

Subcutaneous (SC) Administration

Intramuscular (IM) Administration

#### End Users Covered:

Hospitals

Hemophilia Treatment Centers

Home Care

Ambulatory Surgical Centers

Other End Users

Regions Covered:

North America

US

Canada

Mexico

Europe

Germany

UK

Italy

France

Spain

Rest of Europe

Asia Pacific

Japan

China

India

Australia

New Zealand

South Korea

Rest of Asia Pacific

South America

Argentina

Brazil

Chile

Rest of South America

Middle East & Africa

Saudi Arabia

UAE

Qatar

South Africa

Rest of Middle East & Africa

What our report offers:

- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations

- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

#### Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

##### Company Profiling

Comprehensive profiling of additional market players (up to 3)

SWOT Analysis of key players (up to 3)

##### Regional Segmentation

Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)

##### Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

According to Statistics MRC, the Global Hemophilia Treatment Market is accounted for \$13.7 billion in 2024 and is expected to reach \$20.6 billion by 2030 growing at a CAGR of 7.0% during the forecast period. Hemophilia treatment entails treating and preventing excessive bleeding in people who have hemophilia, a genetic illness that affects blood clotting. In order to restore normal clotting, the main strategy is replacement therapy, which involves injecting clotting factors VIII (for hemophilia A) or IX (for hemophilia B). Additional therapies include gene therapy for long-term correction, antifibrinolytic medications to stop clot breakdown, and desmopressin (DDAVP) for mild cases. Prophylactic (preventive) measures aid in lowering the frequency of unplanned bleeding episodes.

#### Market Dynamics:

## Driver:

### Increasing Prevalence of Hemophilia

The rising prevalence of hemophilia is fueling significant growth in the market. The need for advanced therapeutics, including as gene therapy, recombinant clotting factors, and longer half-life treatments, is being driven by an increase in the number of patients. Prophylactic treatment adoption is increasing as a result of increased patient knowledge and better diagnosis. Market expansion is also being aided by government programs and healthcare subsidies. Pharmaceutical firms are making investments in cutting-edge solutions to satisfy rising demand, which is speeding up market expansion and accessibility.

## Restraint:

### High Treatment Costs

The high cost of hemophilia treatment significantly hinders market growth by limiting patient access to essential therapies. Expensive clotting factor replacement therapies, gene therapies, and prolonged treatment regimens impose a financial burden on healthcare systems and patients, particularly in low- and middle-income countries. This leads to reduced diagnosis rates, treatment discontinuation, and reliance on inadequate alternatives, ultimately restraining market expansion and innovation in hemophilia care.

## Opportunity:

### Expanding Healthcare Infrastructure

Expanding healthcare infrastructure boosts the industry by increasing access to sophisticated medicines, diagnostic facilities, and specialist care. Investing more in clinics, hospitals, and research facilities improves early diagnosis and prompt treatment, which lowers problems. Public-private partnerships, insurance coverage, and government initiatives all contribute to market expansion. Better cold chain logistics and distribution networks also make clotting factor medicines and new gene therapies more widely available, especially in developing nations, which eventually improves patient outcomes and propels market expansion.

## Threat:

## Risk of Inhibitor Development

The risk of inhibitor development negatively impacts the hemophilia treatment market by reducing the effectiveness of standard clotting factor therapies, leading to increased treatment complexity and costs. Patients with inhibitors require alternative, expensive therapies like bypassing agents or gene therapy, limiting market growth. Additionally, managing inhibitors demands frequent monitoring and specialized care, straining healthcare resources. This challenge hinders patient outcomes, discourages treatment adoption, and slows overall market expansion.

## Covid-19 Impact

The COVID-19 pandemic disrupted the hemophilia treatment market by delaying diagnoses, reducing hospital visits, and affecting supply chains. Many patients faced difficulties accessing essential therapies due to lockdowns and healthcare system strain. However, the market saw increased adoption of home-based treatments and digital health solutions. As healthcare systems recovered, demand rebounded, driving innovation in gene therapy and extended half-life treatments for improved patient outcomes.

The gene therapy segment is expected to account for the largest market share during the forecast period

The gene therapy segment is expected to account for the largest market share during the forecast period because long-term factor production is made possible by advanced therapies such as adeno-associated virus (AAV)-based gene transfer, which enhances patient outcomes and quality of life. The market is expanding more quickly because of more approvals, higher R&D expenditures, and growing demand for curative treatments. Furthermore, gene therapy is becoming more and more popular in the treatment of hemophilia due to its lifetime cost-effectiveness when compared to traditional medicines.

The desmopressin segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the desmopressin segment is predicted to witness the highest growth rate, because desmopressin promotes the release of von Willebrand factor and stored factor VIII; it lowers the risk of bleeding and the frequency of clotting factor

infusions. Patient compliance is improved by its simplicity of administration and availability in injectable and intranasal forms. Its demand is further fueled by growing awareness, growing use in emergency situations, and formulation developments, all of which have a favorable impact on the growth of the hemophilia treatment market as a whole.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to growing prevalence of hemophilia, along with favorable reimbursement policies, boosts market growth. Key pharmaceutical advancements, such as extended half-life therapies and recombinant factor products, enhance treatment efficacy. Additionally, government initiatives and research funding support innovation. The presence of major industry players, coupled with patient advocacy groups, further accelerates market expansion. Technological advancements in personalized medicine also contribute to improved treatment outcomes.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, because of easier access to care, especially in developing nations like China and India. Prophylactic treatments are increasingly being used instead of on-demand ones, which is decreasing problems and increasing demand for gene therapy and factor replacement treatments. The availability of treatments is also being improved by partnerships between pharmaceutical companies and healthcare providers, and the market is expanding due to an older population with inherited bleeding problems.

Key players in the market

Some of the key players profiled in the Hemophilia Treatment Market include Takeda Pharmaceutical Company Limited, Octapharma AG., CSL Behring, Medtronic, Pfizer, Inc., Novo Nordisk A/S., Bayer AG, Allergan, BioMarin, Aptevo Therapeutics, Spark Therapeutics, Inc., AscellaHealth, Sanofi, Baxter International and F. Hoffmann La-Roche Ltd.

Key Developments:

In September 2024, Medtronic expanded aible spine surgery ecosystem with new technologies and Siemens Healthineers partnership, These enhancements are

designed to advance AiBLE™, the Medtronic smart ecosystem of innovative navigation, robotics, data and AI, imaging, software and implants that enable more predictable outcomes in spine and cranial procedures.

In August 2024, Pfizer Inc. introduced PfizerForAll, a user-friendly digital platform designed to make access to healthcare and managing health and wellness more seamless for people across the U.S.

#### Hemophilia Types Covered:

Hemophilia A

Hemophilia B

Hemophilia C

Acquired Hemophilia

Other Hemophilia Types

#### Treatment Types Covered:

Factor Replacement Therapies

Desmopressin

Gene Therapy

Antifibrinolytics

Other Treatment Types

#### Administrations Covered:

Intravenous (IV) Administration

Subcutaneous (SC) Administration

## Intramuscular (IM) Administration

### End Users Covered:

Hospitals

Hemophilia Treatment Centers

Home Care

Ambulatory Surgical Centers

Other End Users

### Regions Covered:

North America

US

Canada

Mexico

Europe

Germany

UK

Italy

France

Spain

Rest of Europe

Asia Pacific

Japan

China

India

Australia

New Zealand

South Korea

Rest of Asia Pacific

South America

Argentina

Brazil

Chile

Rest of South America

Middle East & Africa

Saudi Arabia

UAE

Qatar

South Africa

Rest of Middle East & Africa

What our report offers:

- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

#### Company Profiling

Comprehensive profiling of additional market players (up to 3)

SWOT Analysis of key players (up to 3)

#### Regional Segmentation

Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)

#### Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

## Contents

### **1 EXECUTIVE SUMMARY**

### **2 PREFACE**

- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
  - 2.4.1 Data Mining
  - 2.4.2 Data Analysis
  - 2.4.3 Data Validation
  - 2.4.4 Research Approach
- 2.5 Research Sources
  - 2.5.1 Primary Research Sources
  - 2.5.2 Secondary Research Sources
  - 2.5.3 Assumptions

### **3 MARKET TREND ANALYSIS**

- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 End User Analysis
- 3.7 Emerging Markets
- 3.8 Impact of Covid-19

### **4 PORTERS FIVE FORCE ANALYSIS**

- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry

### **5 GLOBAL HEMOPHILIA TREATMENT MARKET, BY HEMOPHILIA TYPE**

*Hemophilia Treatment Market Forecasts to 2030 – Global Analysis By Hemophilia Type (Hemophilia A, Hemophilia B...*

- 5.1 Introduction
- 5.2 Hemophilia A
- 5.3 Hemophilia B
- 5.4 Hemophilia C
- 5.5 Acquired Hemophilia
- 5.6 Other Hemophilia Types

## **6 GLOBAL HEMOPHILIA TREATMENT MARKET, BY TREATMENT TYPE**

- 6.1 Introduction
- 6.2 Factor Replacement Therapies
  - 6.2.1 Recombinant Factor VIII
  - 6.2.2 Recombinant Factor IX
  - 6.2.3 Plasma-derived Products
  - 6.2.4 Extended Half-life Factor Concentrates
- 6.3 Desmopressin
- 6.4 Gene Therapy
- 6.5 Antifibrinolytics
- 6.6 Other Treatment Types

## **7 GLOBAL HEMOPHILIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION**

- 7.1 Introduction
- 7.2 Intravenous (IV) Administration
- 7.3 Subcutaneous (SC) Administration
- 7.4 Intramuscular (IM) Administration

## **8 GLOBAL HEMOPHILIA TREATMENT MARKET, BY END USER**

- 8.1 Introduction
- 8.2 Hospitals
- 8.3 Hemophilia Treatment Centers
- 8.4 Home Care
- 8.5 Ambulatory Surgical Centers
- 8.6 Other End Users

## **9 GLOBAL HEMOPHILIA TREATMENT MARKET, BY GEOGRAPHY**

- 9.1 Introduction
- 9.2 North America
  - 9.2.1 US
  - 9.2.2 Canada
  - 9.2.3 Mexico
- 9.3 Europe
  - 9.3.1 Germany
  - 9.3.2 UK
  - 9.3.3 Italy
  - 9.3.4 France
  - 9.3.5 Spain
  - 9.3.6 Rest of Europe
- 9.4 Asia Pacific
  - 9.4.1 Japan
  - 9.4.2 China
  - 9.4.3 India
  - 9.4.4 Australia
  - 9.4.5 New Zealand
  - 9.4.6 South Korea
  - 9.4.7 Rest of Asia Pacific
- 9.5 South America
  - 9.5.1 Argentina
  - 9.5.2 Brazil
  - 9.5.3 Chile
  - 9.5.4 Rest of South America
- 9.6 Middle East & Africa
  - 9.6.1 Saudi Arabia
  - 9.6.2 UAE
  - 9.6.3 Qatar
  - 9.6.4 South Africa
  - 9.6.5 Rest of Middle East & Africa

## **10 KEY DEVELOPMENTS**

- 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 10.2 Acquisitions & Mergers
- 10.3 New Product Launch
- 10.4 Expansions
- 10.5 Other Key Strategies

## 11 COMPANY PROFILING

11.1 Takeda Pharmaceutical Company Limited

11.2 Octapharma AG.

11.3 CSL Behring

11.4 Medtronic

11.5 Pfizer, Inc.

11.6 Novo Nordisk A/S.

11.7 Bayer AG

11.8 Allergan

11.9 BioMarin

11.10 Aptevo Therapeutics

11.11 Spark Therapeutics, Inc.

11.12 AscellaHealth

11.13 Sanofi

11.14 Baxter International

11.15 F. Hoffmann La-Roche Ltd.

## List Of Tables

### LIST OF TABLES

Table 1 Global Hemophilia Treatment Market Outlook, By Region (2022-2030) (\$MN)

Table 2 Global Hemophilia Treatment Market Outlook, By Hemophilia Type (2022-2030) (\$MN)

Table 3 Global Hemophilia Treatment Market Outlook, By Hemophilia A (2022-2030) (\$MN)

Table 4 Global Hemophilia Treatment Market Outlook, By Hemophilia B (2022-2030) (\$MN)

Table 5 Global Hemophilia Treatment Market Outlook, By Hemophilia C (2022-2030) (\$MN)

Table 6 Global Hemophilia Treatment Market Outlook, By Acquired Hemophilia (2022-2030) (\$MN)

Table 7 Global Hemophilia Treatment Market Outlook, By Other Hemophilia Types (2022-2030) (\$MN)

Table 8 Global Hemophilia Treatment Market Outlook, By Treatment Type (2022-2030) (\$MN)

Table 9 Global Hemophilia Treatment Market Outlook, By Factor Replacement Therapies (2022-2030) (\$MN)

Table 10 Global Hemophilia Treatment Market Outlook, By Recombinant Factor VIII (2022-2030) (\$MN)

Table 11 Global Hemophilia Treatment Market Outlook, By Recombinant Factor IX (2022-2030) (\$MN)

Table 12 Global Hemophilia Treatment Market Outlook, By Plasma-derived Products (2022-2030) (\$MN)

Table 13 Global Hemophilia Treatment Market Outlook, By Extended Half-life Factor Concentrates (2022-2030) (\$MN)

Table 14 Global Hemophilia Treatment Market Outlook, By Desmopressin (2022-2030) (\$MN)

Table 15 Global Hemophilia Treatment Market Outlook, By Gene Therapy (2022-2030) (\$MN)

Table 16 Global Hemophilia Treatment Market Outlook, By Antifibrinolytics (2022-2030) (\$MN)

Table 17 Global Hemophilia Treatment Market Outlook, By Other Treatment Types (2022-2030) (\$MN)

Table 18 Global Hemophilia Treatment Market Outlook, By Route of Administration (2022-2030) (\$MN)

Table 19 Global Hemophilia Treatment Market Outlook, By Intravenous (IV) Administration (2022-2030) (\$MN)

Table 20 Global Hemophilia Treatment Market Outlook, By Subcutaneous (SC) Administration (2022-2030) (\$MN)

Table 21 Global Hemophilia Treatment Market Outlook, By Intramuscular (IM) Administration (2022-2030) (\$MN)

Table 22 Global Hemophilia Treatment Market Outlook, By End User (2022-2030) (\$MN)

Table 23 Global Hemophilia Treatment Market Outlook, By Hospitals (2022-2030) (\$MN)

Table 24 Global Hemophilia Treatment Market Outlook, By Hemophilia Treatment Centers (2022-2030) (\$MN)

Table 25 Global Hemophilia Treatment Market Outlook, By Home Care (2022-2030) (\$MN)

Table 26 Global Hemophilia Treatment Market Outlook, By Ambulatory Surgical Centers (2022-2030) (\$MN)

Table 27 Global Hemophilia Treatment Market Outlook, By Other End Users (2022-2030) (\$MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

## I would like to order

Product name: Hemophilia Treatment Market Forecasts to 2030 – Global Analysis By Hemophilia Type (Hemophilia A, Hemophilia B, Hemophilia C, Acquired Hemophilia and Other Hemophilia Types), Treatment Type, Route of Administration, End User and By Geography

Product link: <https://marketpublishers.com/r/HCCFD28ECCE2EN.html>

Price: US\$ 4,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HCCFD28ECCE2EN.html>